GLP-1 linked to lower cancer progression in 12,112 patients

ASCO said on May 21 that real-world data from 12,112 patients suggested GLP-1 receptor agonists were linked to lower odds of metastatic progression in four obesity-related cancers. The findings cover patients with stage I, II or III lung, breast, colorectal and liver cancers and will be presented at the American Society of Clinical Oncology’s annual meeting in Chicago from May 29 to June 2. The study adds to a widening body of research around GLP-1 drugs, which are already widely used for diabetes and obesity. This analysis did not test whether the drugs prevent cancer from developing; it examined whether cancers that had already been diagnosed were less likely to advance to stage IV in patients taking GLP-1s. ### What exactly did the researchers study? (asco.org) ASCO said the analysis used real-world data to compare GLP-1 receptor agonists with DPP-4 inhibitors, also known as gliptins, across seven obesity-related cancers. The seven cancers were breast adenocarcinoma, prostate adenocarcinoma, non-small cell lung cancer, colorectal adenocarcinoma, hepatocellular carcinoma, renal cell carcinoma and pancreatic adenocarcinoma. (asco.org) ASCO’s patient summary said investigators reviewed health records from more than 12,000 people around the world whose cancers were at stages I through III, meaning the disease had not yet spread to distant sites. Half were taking a GLP-1 drug and half were taking a gliptin. ### Which cancers showed the clearest signal? ASCO said four of the seven cancers met the threshold for a statistically significant reduction in progression to stage IV: lung, breast, colorectal and liver cancer. (asco.org) Oncology Central, citing the same ASCO material, reported that patients with those cancers taking GLP-1s showed a 38% to 50% lower risk of metastatic progression. (asco.org) NBC News reported that the largest reductions were seen in lung and breast cancer. According to NBC’s account of the study, patients with lung cancer taking GLP-1s were 50% less likely to progress to stage IV than matched patients taking a DPP-4 inhibitor, while breast cancer patients were 43% less likely to progress. (asco.org) ### How was the comparison set up? NBC News reported that the research was led by Dr. Mark Orland of Cleveland Clinic and used patient records from the TriNetX Global Health Research Network database. NBC said the researchers identified more than 10,000 patients diagnosed with one of seven cancer types who started a GLP-1 drug after their cancer diagnosis, then matched them to similar patients who instead started a DPP-4 inhibitor. (nbcnews.com) ASCO said both drug classes manage diabetes through metabolism and blood sugar control, but GLP-1s are more potent and have stronger anti-inflammatory effects than gliptins. ASCO expert Marcin Chwistek of Fox Chase Cancer Center said in a statement that the drugs’ anti-inflammatory and immune-modulatory properties had long suggested broader effects, and that data this large and consistent warranted a prospective randomized trial. (nbcnews.com) ### What are the main limits on the findings? NBC News said the study was observational and has not yet been published in a peer-reviewed journal. That means it can show an association, not prove that GLP-1 drugs caused the lower progression rates. ASCO’s patient summary also described the results as early support that GLP-1s may help keep certain cancers from worsening. (asco.org) The organization said fewer people taking GLP-1s developed stage IV disease in those four cancer types than people taking gliptins. ### What happens next? ASCO said the data will be presented at its 2026 annual meeting in Chicago, which runs from May 29 through June 2. (nbcnews.com) Chwistek said the next step should be a prospective randomized trial, a study design that could test whether the relationship holds up under controlled conditions. (asco.org 1) (asco.org 2)